All Stories

  1. Post-COVID-19 Syndrome as Described by Patients: A Qualitative Study

    Article • Healthcare, March 2025, MDPI AG

    Dr Marco Colizzi

  2. Editorial: Case reports in autism: 2023

    Article • Frontiers in Psychiatry, February 2025, Frontiers

    Dr Marco Colizzi

  3. Palmitoylethanolamide supplementation for human health: A state-of-the-art systematic review of Randomized Controlled Trials in patient populations

    Article • Brain Behavior & Immunity - Health, February 2025, Elsevier

    Dr Marco Colizzi

  4. In Web We Trust: The Promised Cannabidiol Effects on Obesity as a Matter of Language and Marketing on Webpages

    Article • Current Neuropharmacology, January 2025, Bentham Science Publishers

    Dr Marco Colizzi

  5. Collaborative outcomes study on health and functioning during infection times (COH-FIT): Insights on modifiable and non-modifiable risk and protective factors for wellbeing and mental health during the COVID-19 pandemic from multivariable and network a...

    Article • European Neuropsychopharmacology, January 2025, Elsevier

    Dr Marco Colizzi, Ching-Fang Sun

  6. The Moderating Role of Genetic and Environmental Risk Factors for Schizophrenia on the Relationship between Autistic Traits and Psychosis Expression in the General Population

    Article • Schizophrenia Bulletin Open, January 2025, Oxford University Press (OUP)

    Dr Marco Colizzi

  7. The Endocannabinoid Activity Remodulation for Psychosis Liability in Youth (EARLY) Study: An Open-Label Feasibility Trial of Ultramicronized-Palmitoylethanolamide Oral Supplementation in Clinical High-Risk State for Psychosis

    Article • Brain Sciences, December 2024, MDPI AG

    Dr Marco Colizzi

  8. Clinical heterogeneity of feeding and eating disorders: using personality psychopathology to differentiate “simplex” and “complex” phenotypes

    Article • BMC Psychiatry, December 2024, Springer Science + Business Media

    Dr Marco Colizzi

  9. Is a No-Restraint Policy Associated with Increased Aggression Towards Healthcare Professionals Among Inpatient Psychiatric Units? A 16-Year Retrospective Observational Study Conducted in Italy

    Article • Nursing Reports, December 2024, MDPI AG

    Dr Marco Colizzi

  10. Global and risk-group stratified well-being and mental health during the COVID-19 pandemic in adults: Results from the international COH-FIT Study

    Article • Psychiatry Research, December 2024, Elsevier

    Ching-Fang Sun, Dr Marco Colizzi

  11. Challenges in addressing youth mental health

    Article • The Lancet Psychiatry, December 2024, Elsevier

    Dr Marco Colizzi

  12. Collaborative Outcomes Study on Health and Functioning During Infection Times (COH-FIT): Global and Risk-Group Stratified Course of Well-Being and Mental Health During the COVID-19 Pandemic in Adolescents

    Article • Journal of the American Academy of Child & Adolescent Psychiatry, November 2024, Elsevier

    Dr Marco Colizzi

  13. Occupational Stress Among Italian Postgraduate Medical Trainees: A Pilot Study for the Validation of the SCOPE Questionnaire

    Article • Psychiatry International, October 2024, MDPI AG

    Dr Marco Colizzi

  14. Assessing the biobehavioral effects of ultramicronized-palmitoylethanolamide monotherapy in autistic adults with different severity levels: a report of two cases

    Article • Frontiers in Psychiatry, October 2024, Frontiers

    Dr Marco Colizzi

  15. Lessons Learnt From Running a Transition‐Age Youth Mental Health Outpatient Clinic in Italy: The PRecocity of Intervention in Adolescent Medicine (PRIMA) Experience

    Article • Early Intervention in Psychiatry, August 2024, Wiley

    Dr Marco Colizzi

  16. Cannabidiol (CBD) Listed as a Drug of Abuse by the Italian Health Ministry: Expert Opinion

    Article • Current Social Sciences, August 2024, Bentham Science Publishers

    Dr Marco Colizzi

  17. CaReL Guideline: A Consensus-Based Guideline on Case Reports and Literature Review (CaReL)

    Article • Barw Medical Journal, June 2024, Barw Medical Journal

    Dr Marco Colizzi

  18. The Supplementation Therapy in Autism and Response to Treatment (START) Study: An Open-Label Feasibility Trial of Ultramicronized Palmitoylethanolamide Potential to Alleviate Psychic Distress among Autistic Adults

    Article • Clinical and Translational Neuroscience, May 2024, MDPI AG

    Dr Marco Colizzi

  19. Prevalence and risk factors for depression in factitious disorder: a systematic review

    Article • Frontiers in Psychiatry, April 2024, Frontiers

    Dr Marco Colizzi

  20. Tic-Related Obsessive–Compulsive and Eating Disorders in Dandy–Walker Variant: A Case Report and Systematic Reappraisal of Psychiatric Profiles

    Article • Brain Sciences, April 2024, MDPI AG

    Dr Marco Colizzi

  21. Prenatal insomnia disorder may predict concurrent and postpartum psychopathology: A longitudinal study

    Article • Journal of Sleep Research, March 2024, Wiley

    Dr Marco Colizzi

  22. COVID-19-induced neuropsychiatric symptoms can persist long after acute infection: a 2-year prospective study of biobehavioral risk factors and psychometric outcomes

    Article • Irish Journal of Psychological Medicine, February 2024, Cambridge University Press

    Dr Marco Colizzi

  23. Editorial: Case reports in autism

    Article • Frontiers in Psychiatry, January 2024, Frontiers

    Dr Marco Colizzi

  24. Pediatric emergency department mental health assessments in the 2 years following the COVID-19 outbreak reveal higher vulnerability for eating disorder and suicide risk

    Article • Journal of Affective Disorders Reports, January 2024, Elsevier

    Dr Marco Colizzi

  25. Impact of COVID-19 on behavior in autism spectrum disorder

    Article • January 2024, Elsevier

    Dr Marco Colizzi

  26. Risk of psychosis in autism spectrum disorder individuals exposed to psychosocial stressors: A 9‐year chart review study

    Article • Autism Research, November 2023, Wiley

    Dr Marco Colizzi

  27. Lessons learnt while designing and conducting a longitudinal study from the first Italian COVID-19 pandemic wave up to 3 years

    Article • Health Research Policy and Systems, October 2023, Springer Science + Business Media

    Dr Marco Colizzi

  28. Psychological factors associated with vaccination hesitancy: an observational study of patients hospitalized for COVID-19 in a later phase of the pandemic in Italy

    Article • Frontiers in Psychiatry, October 2023, Frontiers

    Dr Marco Colizzi

  29. Editorial: Advances in understanding the pathogenetic mechanisms of neurodevelopmental disorders and neurodegenerative disease — The environment as a putative risk factor

    Article • Frontiers in Neurology, August 2023, Frontiers

    Dr Marco Colizzi

  30. Biobehavioral Interactions between Endocannabinoid and Hypothalamic-pituitary-adrenal Systems in Psychosis: A Systematic Review

    Article • Current Neuropharmacology, August 2023, Bentham Science Publishers

    Dr Marco Colizzi

  31. Questioning the role of palmitoylethanolamide in psychosis: a systematic review of clinical and preclinical evidence

    Article • Frontiers in Psychiatry, July 2023, Frontiers

    Dr Marco Colizzi

  32. COVID-19 Survivors Are Still in Need of Neuropsychiatric Support Two Years after Infection

    Article • Brain Sciences, July 2023, MDPI AG

    Dr Marco Colizzi

  33. Editorial: Developmental trajectories in mental health between adolescence and adulthood

    Article • Frontiers in Psychiatry, June 2023, Frontiers

    Dr Marco Colizzi

  34. Confirmation of increased and more severe adolescent mental health-related in-patient admissions in the COVID-19 pandemic aftermath: A 2-year follow-up study

    Article • Psychiatry Research Communications, June 2023, Elsevier

    Dr Marco Colizzi

  35. Stressful life events and relapse of psychosis: analysis of causal association in a 2-year prospective observational cohort of individuals with first-episode psychosis in the UK

    Article • The Lancet Psychiatry, June 2023, Elsevier

    Dr Marco Colizzi

  36. Mentalization in young patients undergoing opioid agonist treatment: Implications for clinical management

    Article • Addictive Behaviors Reports, June 2023, Elsevier

    Dr Marco Colizzi

  37. Changes in Revolving-Door Mental Health Hospitalizations during the COVID-19 Pandemic: A 5-Year Chart Review Study

    Article • Journal of Clinical Medicine, April 2023, MDPI AG

    Dr Marco Colizzi

  38. Where Do Neurodevelopmental Disorders Go? Casting the Eye Away from Childhood towards Adulthood

    Article • Healthcare, April 2023, MDPI AG

    Dr Marco Colizzi

  39. Association between stressful life events and psychosis relapse: a 2‐year prospective study in first‐episode psychosis

    Article • World Psychiatry, January 2023, Wiley

    Dr Marco Colizzi

  40. Using Metaphors to Understand Suffering in COVID-19 Survivors: A Two Time-Point Observational Follow-Up Study

    Article • International Journal of Environmental Research and Public Health, January 2023, MDPI AG

    Dr Marco Colizzi

  41. Prevalence and Risk Factors for Absconding from an Open-Door, No-Restraint Inpatient Psychiatric Unit: A Single-Center Study in Italy

    Article • Behavioral Sciences, January 2023, MDPI AG

    Dr Marco Colizzi

  42. Uncovering Mental Health Insights: Exploring Cannabis and Psychosis Link in the UK

    Article • Epidemiology and Psychiatric Sciences, January 2023, Cambridge University Press

    Dr Marco Colizzi

  43. Editorial: Methods and applications in addiction psychiatry research: 2021

    Article • Frontiers in Psychiatry, December 2022, Frontiers

    Dr Marco Colizzi

  44. Development and Reliability of a Questionnaire Assessing Stress, Coping, and Empathy (SCOPE) in Occupational Settings: Preliminary Evidence from Veterinarians

    Article • Psychiatry International, December 2022, MDPI AG

    Dr Marco Colizzi

  45. Validation of the collaborative outcomes study on health and functioning during infection times (COH-FIT) questionnaire for adults

    Article • Journal of Affective Disorders, December 2022, Elsevier

    Dr Marco Colizzi, Prof Philip Ward, Professor Jari Tiihonen

  46. Therapeutic effect of palmitoylethanolamide in cognitive decline: A systematic review and preliminary meta-analysis of preclinical and clinical evidence

    Article • Frontiers in Psychiatry, October 2022, Frontiers

    Dr Marco Colizzi

  47. Feigning Capgras Syndrome and Developmental Prosopagnosia: a rare case of Pediatric Factitious Disorder?

    Article • Current Psychiatry Research and Reviews, August 2022, Bentham Science Publishers

    Dr Marco Colizzi

  48. Cannabis Use in Autism: Reasons for Concern about Risk for Psychosis

    Article • Healthcare, August 2022, MDPI AG

    Dr Marco Colizzi

  49. Mental health symptoms one year after acute COVID-19 infection: prevalence and risk factors

    Article • Revista de Psiquiatría y Salud Mental, June 2022, Elsevier

    Dr Marco Colizzi

  50. The Autism–Psychosis Continuum Conundrum: Exploring the Role of the Endocannabinoid System

    Article • International Journal of Environmental Research and Public Health, May 2022, MDPI AG

    Dr Marco Colizzi

  51. Sociodemographic and clinical changes in pediatric in-patient admissions for mental health emergencies during the COVID-19 pandemic: March 2020 to June 2021

    Article • Psychiatry Research Communications, March 2022, Elsevier

    Dr Marco Colizzi

  52. Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A)

    Article • Journal of Affective Disorders, February 2022, Elsevier

    Dr Marco Colizzi, Ching-Fang Sun, Prof Philip Ward

  53. The collaborative outcomes study on health and functioning during infection times in adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic

    Article • Journal of Affective Disorders, February 2022, Elsevier

    Dr Marco Colizzi, Ching-Fang Sun, Prof Philip Ward, Professor Jari Tiihonen

  54. Gender-Oriented Mental Health Prevention: A Reappraisal

    Article • International Journal of Environmental Research and Public Health, January 2022, MDPI AG

    Dr Marco Colizzi

  55. Is It Time to Test the Antiseizure Potential of Palmitoylethanolamide in Human Studies? A Systematic Review of Preclinical Evidence

    Article • Brain Sciences, January 2022, MDPI AG

    Dr Marco Colizzi

  56. Neurodevelopmental Disorders and Psychosocial Issues Later in Life

    Article • January 2022, Springer Science + Business Media

    Dr Marco Colizzi

  57. Prevention in Mental Health

    Article • January 2022, Springer Science + Business Media

    Dr Marco Colizzi

  58. Further evidence on the interplay between benzodiazepine and Z-drug abuse and emotion dysregulation

    Article • Journal of Affective Disorders Reports, December 2021, Elsevier

    Dr Marco Colizzi

  59. Additional Evidence for Neuropsychiatric Manifestations in Mosaic Trisomy 20: A Case Report and Brief Review

    Article • Children, November 2021, MDPI AG

    Dr Marco Colizzi

  60. Meet the Editorial Board Member

    Article • Current Psychiatry Research and Reviews, November 2021, Bentham Science Publishers

    Dr Marco Colizzi

  61. Editorial: The Endocannabinoid System: Filling the Translational Gap Between Neuroscience and Psychiatry

    Article • Frontiers in Psychiatry, October 2021, Frontiers

    Dr Marco Colizzi

  62. 21.5 Repercussions of the First and Second COVID-19 Waves in the Italian Pediatric Population: An Inpatient Psychiatric Emergency Study

    Article • Journal of the American Academy of Child & Adolescent Psychiatry, October 2021, Elsevier

    Dr Marco Colizzi

  63. Vortioxetine Add-On to Methylphenidate for the Treatment of Symptoms of Sickness Behavior in Attention-Deficit Hyperactivity Disorder: Report of Two Cases

    Article • Reports — Medical Cases Images and Videos, September 2021, MDPI AG

    Dr Marco Colizzi

  64. Epigenetic Mediation of AKT1 rs1130233’s Effect on Delta-9-Tetrahydrocannabinol-Induced Medial Temporal Function during Fear Processing

    Article • Brain Sciences, September 2021, MDPI AG

    Dr Marco Colizzi

  65. Palmitoylethanolamide and Its Biobehavioral Correlates in Autism Spectrum Disorder: A Systematic Review of Human and Animal Evidence

    Article • Nutrients, April 2021, MDPI AG

    Dr Marco Colizzi

  66. Effectiveness of Equine-Assisted Activities and Therapies for Improving Adaptive Behavior and Motor Function in Autism Spectrum Disorder

    Article • Journal of Clinical Medicine, April 2021, MDPI AG

    Dr Marco Colizzi

  67. Postural Control in Childhood: Investigating the Neurodevelopmental Gradient Hypothesis

    Article • International Journal of Environmental Research and Public Health, February 2021, MDPI AG

    Dr Marco Colizzi

  68. The Effectiveness of Lurasidone Add-On for Residual Aggressive Behavior and Obsessive Symptoms in Antipsychotic-Treated Children and Adolescents with Tourette Syndrome: Preliminary Evidence from a Case Series

    Article • Children, February 2021, MDPI AG

    Dr Marco Colizzi

  69. Cannabis: Neuropsychiatry and Its Effects on Brain and Behavior

    Article • Brain Sciences, November 2020, MDPI AG

    Dr Marco Colizzi

  70. Adolescent Lifestyle Behaviors, Coping Strategies and Subjective Wellbeing during the COVID-19 Pandemic: An Online Student Survey

    Article • Healthcare, November 2020, MDPI AG

    Dr Marco Colizzi

  71. Differential sensitivity to the acute psychotomimetic effects of delta-9-tetrahydrocannabinol associated with its differential acute effects on glial function and cortisol

    Article • Psychological Medicine, October 2020, Cambridge University Press

    Dr Marco Colizzi

  72. 4.4 IS ALTERED SENSORIMOTOR INTEGRATION A CORE FEATURE OF TOURETTE'S DISORDER? A CASE-CONTROL STUDY

    Article • Journal of the American Academy of Child & Adolescent Psychiatry, October 2020, Elsevier

    Dr Marco Colizzi

  73. 51.18 THE COVID-19 OUTBREAK IMPACT ON WELL-BEING AMONG PEOPLE WITH AUTISM SPECTRUM DISORDER IN ITALY: AN N = 527 WEB-BASED SURVEY

    Article • Journal of the American Academy of Child & Adolescent Psychiatry, October 2020, Elsevier

    Dr Marco Colizzi

  74. Investigating Gait, Movement, and Coordination in Children with Neurodevelopmental Disorders: Is There a Role for Motor Abnormalities in Atypical Neurodevelopment?

    Article • Brain Sciences, September 2020, MDPI AG

    Dr Marco Colizzi

  75. Is the Adolescent Brain at Greater Vulnerability to the Effects of Cannabis? A Narrative Review of the Evidence

    Article • Frontiers in Psychiatry, August 2020, Frontiers

    Dr Marco Colizzi

  76. Psychosocial and Behavioral Impact of COVID-19 in Autism Spectrum Disorder: An Online Parent Survey

    Article • Brain Sciences, June 2020, MDPI AG

    Dr Marco Colizzi

  77. Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition

    Article • Frontiers in Psychology, May 2020, Frontiers

    Dr Marco Colizzi

  78. Medically unexplained symptoms in the times of COVID-19 pandemic: A case-report

    Article • Brain Behavior & Immunity - Health, May 2020, Elsevier

    Dr Marco Colizzi

  79. Association of cannabis with glutamatergic levels in patients with early psychosis: Evidence for altered volume striatal glutamate relationships in patients with a history of cannabis use in early psychosis

    Article • Translational Psychiatry, April 2020, Springer Science + Business Media

    Dr Marco Colizzi

  80. Prevention and early intervention in youth mental health: is it time for a multidisciplinary and trans-diagnostic model for care?

    Article • International Journal of Mental Health Systems, March 2020, Springer Science + Business Media

    Dr Marco Colizzi

  81. Cannabis and Cognition: Connecting the Dots towards the Understanding of the Relationship

    Article • Brain Sciences, February 2020, MDPI AG

    Dr Marco Colizzi

  82. Should we be concerned about stigma and discrimination in people at risk for psychosis? A systematic review

    Article • Psychological Medicine, February 2020, Cambridge University Press

    Dr Marco Colizzi

  83. The influence of risk factors on the onset and outcome of psychosis: What we learned from the GAP study

    Article • Schizophrenia Research, February 2020, Elsevier

    Dr Marco Colizzi

  84. The 2019 Schizophrenia International Research Society Conference, 10–14 April, Orlando, Florida: A summary of topics and trends

    Article • Psychiatry Research, February 2020, Elsevier

    Dr Marco Colizzi, Tina Dam Kristensen

  85. Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis

    Article • Psychological Medicine, January 2020, Cambridge University Press

    Dr Marco Colizzi

  86. Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis

    Article • Psychopharmacology, January 2020, Springer Science + Business Media

    Dr Marco Colizzi

  87. Is there sufficient evidence that cannabis use is a risk factor for psychosis?

    Article • January 2020, Elsevier

    Dr Marco Colizzi

  88. Stigma as the main obstacle in health care and human rights among people with mental disorders. A rights-based ethics approach

    Article • RIVISTA SPERIMENTALE DI FRENIATRIA, November 2019, Franco Angeli

    Dr Marco Colizzi

  89. Childhood trauma and being at-risk for psychosis are associated with higher peripheral endocannabinoids

    Article • Psychological Medicine, August 2019, Cambridge University Press

    Dr Marco Colizzi

  90. Effect of lifestyle, medication and ethnicity on cardiometabolic risk in the year following the first episode of psychosis: prospective cohort study

    Article • The British Journal of Psychiatry, July 2019, Royal College of Psychiatrists

    Dr Marco Colizzi

  91. Differential gene expression analysis in blood of first episode psychosis patients

    Article • Schizophrenia Research, May 2019, Elsevier

    Dr Marco Colizzi

  92. Descriptive Psychopathology of the Acute Effects of Intravenous Delta-9-Tetrahydrocannabinol Administration in Humans

    Article • Brain Sciences, April 2019, MDPI AG

    Dr Marco Colizzi

  93. O3.4. DOES CANNABIS INDUCE PSYCHOSIS BY ALTERING GLUTAMATE SIGNALING IN THE STRIATUM?

    Article • Schizophrenia Bulletin, April 2019, Oxford University Press (OUP)

    Dr Marco Colizzi

  94. Interaction between childhood adversity and functional polymorphisms in the dopamine pathway on first-episode psychosis

    Article • Schizophrenia Research, March 2019, Elsevier

    Dr Marco Colizzi

  95. Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis

    Article • Molecular Psychiatry, February 2019, Springer Science + Business Media

    Dr Marco Colizzi

  96. The Relationship Between Dissociative Experiences and Cannabis Use: a Systematic Review

    Article • Current Addiction Reports, January 2019, Springer Science + Business Media

    Dr Marco Colizzi

  97. Correction to: The Neural Substrate of Reward Anticipation in Health: A Meta-Analysis of fMRI Findings in the Monetary Incentive Delay Task

    Article • Neuropsychology Review, December 2018, Springer Science + Business Media

    Dr Marco Colizzi

  98. Jumping to conclusions at first onset of psychosis predicts longer admissions, more compulsory admissions and police involvement over the next 4 years: the GAP study

    Article • Psychological Medicine, November 2018, Cambridge University Press

    Victoria Rodriguez, Dr Marco Colizzi

  99. Longitudinal assessment of the effect of cannabis use on hospital readmission rates in early psychosis: A 6-year follow-up in an inpatient cohort

    Article • Psychiatry Research, October 2018, Elsevier

    Dr Marco Colizzi

  100. Cannabis use and the development of tolerance: a systematic review of human evidence

    Article • Neuroscience & Biobehavioral Reviews, October 2018, Elsevier

    Dr Marco Colizzi

  101. The Neural Substrate of Reward Anticipation in Health: A Meta-Analysis of fMRI Findings in the Monetary Incentive Delay Task

    Article • Neuropsychology Review, September 2018, Springer Science + Business Media

    Dr Marco Colizzi

  102. Previous cannabis exposure modulates the acute effects of delta-9-tetrahydrocannabinol on attentional salience and fear processing.

    Article • Experimental and Clinical Psychopharmacology, August 2018, American Psychological Association (APA)

    Prof Sagnik Bhattacharyya, Dr Marco Colizzi

  103. Modulation of acute effects of delta-9-tetrahydrocannabinol on psychotomimetic effects, cognition and brain function by previous cannabis exposure

    Article • European Neuropsychopharmacology, July 2018, Elsevier

    Dr Marco Colizzi

  104. S152. CANNABIDIOL INDUCED MODULATION OF MEDIOTEMPORAL ACTIVITY DURING A VERBAL MEMORY TASK IN FIRST-EPISODE PSYCHOSIS

    Article • Schizophrenia Bulletin, April 2018, Oxford University Press (OUP)

    Dr Marco Colizzi

  105. F68. PREMORBID IQ, EDUCATIONAL LEVEL AND JUMPING TO CONCLUSIONS AS PREDICTORS OF CLINICAL OUTCOME AT FIRST ONSET OF PSYCHOSIS OVER THE NEXT 4 YEARS: THE GAP STUDY

    Article • Schizophrenia Bulletin, April 2018, Oxford University Press (OUP)

    Dr Marco Colizzi

  106. S224. DELTA-9-TETRAHYDROCANNABINOL CHALLENGE IN CANNABIS USERS AND NON-USERS DIFFERENTIALLY AFFECTS BRAIN FUNCTION AND BEHAVIOR: AN FMRI STUDY OF DEVELOPMENT OF TOLERANCE

    Article • Schizophrenia Bulletin, April 2018, Oxford University Press (OUP)

    Dr Marco Colizzi

  107. Cannabis and psychosis: what do we know and what should we do?

    Article • The British Journal of Psychiatry, March 2018, Royal College of Psychiatrists

    Dr Marco Colizzi

  108. Do Cannabis Users Develop Tolerance for the Psychoactive Effects of Delta-9-tetrahydrocannabinol? an fMRI Study

    Article • February 2018, Morressier

    Dr Marco Colizzi

  109. Neurocognitive effects of cannabis: Lessons learned from human experimental studies

    Article • January 2018, Elsevier

    Dr Marco Colizzi

  110. Associations between psychosis endophenotypes across brain functional, structural, and cognitive domains

    Article • Psychological Medicine, November 2017, Cambridge University Press

    Dr Marco Colizzi, Alvaro Diez

  111. Hyperprolactinaemia in first episode psychosis - A longitudinal assessment

    Article • Schizophrenia Research, November 2017, Elsevier

    Dr Marco Colizzi

  112. Does Cannabis Composition Matter? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition

    Article • Current Addiction Reports, April 2017, Springer Science + Business Media

    Prof Sagnik Bhattacharyya, Dr Marco Colizzi

  113. Cannabis users are less sensitive to the acute psychotomimetic effects of delta-9-tetrahydrocannabinol administration

    Article • European Neuropsychopharmacology, March 2017, Elsevier

    Dr Marco Colizzi

  114. A Prediction Modelling and Pattern Detection Approach for the First-Episode Psychosis Associated to Cannabis Use

    Article • December 2016, Institute of Electrical & Electronics Engineers (IEEE)

    Dr Marco Colizzi

  115. Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study

    Article • The Lancet Psychiatry, October 2016, Elsevier

    Dr Marco Colizzi

  116. The effect of cross-sex hormonal treatment on gender dysphoria individuals' mental health: a systematic review

    Article • August 2016, Dove Medical Press

    Dr Marco Colizzi

  117. Prefrontal activity during working memory is modulated by the interaction of variation in CB1 and COX2 coding genes and correlates with frequency of cannabis use

    Article • Cortex, August 2016, Elsevier

    Dr Marco Colizzi

  118. To treat or not to treat: puberty suppression in childhood-onset gender dysphoria

    Article • Nature Reviews Urology, July 2016, Nature

    Dr Marco Colizzi

  119. Effect of cannabis on glutamate signalling in the brain: A systematic review of human and animal evidence

    Article • Neuroscience & Biobehavioral Reviews, May 2016, Elsevier

    Prof Sagnik Bhattacharyya, Dr Marco Colizzi

  120. Substance use, medication adherence and outcome one year following a first episode of psychosis

    Article • Schizophrenia Research, February 2016, Elsevier

    Dr Marco Colizzi

  121. Interaction between DRD2 and AKT1 genetic variations on risk of psychosis in cannabis users: a case–control study

    Article • Schizophrenia, December 2015, Nature

    Dr Marco Colizzi

  122. Concomitant psychiatric problems and hormonal treatment induced metabolic syndrome in gender dysphoria individuals: A 2year follow-up study

    Article • Journal of Psychosomatic Research, April 2015, Elsevier

    Dr Marco Colizzi

  123. Interaction Between Functional Genetic Variation of DRD2 and Cannabis Use on Risk of Psychosis

    Article • Schizophrenia Bulletin, March 2015, Oxford University Press (OUP)

    Dr Marco Colizzi

  124. Dissociative symptoms in individuals with gender dysphoria: Is the elevated prevalence real?

    Article • Psychiatry Research, March 2015, Elsevier

    Dr Marco Colizzi

  125. Psychological Support, Puberty Suppression, and Psychosocial Functioning in Adolescents with Gender Dysphoria

    Article • The Journal of Sexual Medicine, January 2015, Elsevier

    Dr Marco Colizzi

  126. Functional Genetic Variation of the Cannabinoid Receptor 1 and Cannabis Use Interact on Prefrontal Connectivity and Related Working Memory Behavior

    Article • Neuropsychopharmacology, August 2014, Nature

    Dr Marco Colizzi

  127. Poster #M195 THE INTERACTION BETWEEN CNR1 GENETIC VARIATION AND CANNABIS EXPOSURE PREDICTS PREFRONTAL FUNCTIONAL CONNECTIVITY AND BEHAVIOR DURING WORKING MEMORY

    Article • Schizophrenia Research, April 2014, Elsevier

    Dr Marco Colizzi

  128. Attachment Styles in Transsexual Patients and Clinical and Nonclinical Control Groups: A Response

    Article • The Journal of Sexual Medicine, April 2014, Elsevier

    Dr Marco Colizzi

  129. Transsexual patients’ psychiatric comorbidity and positive effect of cross-sex hormonal treatment on mental health: Results from a longitudinal study

    Article • Psychoneuroendocrinology, January 2014, Elsevier

    Dr Marco Colizzi

  130. Hormonal Treatment Reduces Psychobiological Distress in Gender Identity Disorder, Independently of the Attachment Style

    Article • The Journal of Sexual Medicine, December 2013, Elsevier

    Dr Marco Colizzi

  131. Poster #103 INTERACTION BETWEEN COMT GENOTYPE, CANNABIS USE, AND BFQ MEASURES OF SOCIABILITY

    Article • Schizophrenia Research, April 2012, Elsevier

    Dr Marco Colizzi

  132. Poster #35 STUDYING EPISODIC MEMORY CEREBRAL NETWORK: A NOVEL EVENT-RELATED TASK FOR FMRI

    Article • Schizophrenia Research, April 2012, Elsevier

    Dr Marco Colizzi

  133. COGNITIVE DEFICITS AS INTERMEDIATE PHENOTYPE IN SCHIZOPHRENIA

    Article • Schizophrenia Research, April 2010, Elsevier

    Dr Marco Colizzi